How Amarin Beat Wall Street's Q4 Estimates
2020 was an outright disaster for Amarin (NASDAQ: AMRN). Its stock plunged 77% because the drugmaker lost a key patent lawsuit over its flagship product Vascepa. But 2021 has been much better for Amarin so far. Good news related to the initiation of the regulatory review process for Vascepa in China and Hong Kong has been one of several factors behind the stock's year-to-date gain of more than 50%.
That momentum should continue after the company announced its fourth-quarter results before the market opened on Thursday. Here are the highlights from the update.
Image source: Getty Images.
Source Fool.com
